FDA clears SimBioSys software to estimate breast cancer recurrence risk
The U.S. FDA cleared SimBioSys’s TumorSight Risk software, which estimates breast cancer recurrence risk using breast MRI scans and clinical factors. The software provides five- and 10-year risk scores, according to FOX 5 Atlanta.
AI-assisted synthesis · Based on 4 independent reports from 5 outlets · Full text read from 1 of 4 reportsHow it's made
View timeline · 1 entryWhat happened
Key facts
- The software is named TumorSight Risk (per fox5atlanta.com, prnewswire.com).
- SimBioSys is based in Chicago (per fox5atlanta.com).
- SimBioSys President and CEO Stacey Stevens said MRI information, pathology and clinical factors can provide clinicians with insight into recurrence risk (per fox5atlanta.com).
The brief
The U.S. FDA cleared SimBioSys’s TumorSight Risk software, an AI tool designed to estimate breast cancer recurrence risk using patient MRI scans and existing clinical factors, FOX 5 Atlanta reported. The clearance was announced by SimBioSys, a Chicago-based company that the outlet describes as specializing in AI-driven medicine.
The software calculates recurrence-risk estimates for two periods: five years and 10 years. FOX 5 Atlanta said FDA documents state that the software generates those estimates. The outlet also reported that TumorSight Risk produces a score on a scale from 0 to 100 and assigns the result to a high, intermediate or low risk category.
SimBioSys President and CEO Stacey Stevens described the system as combining information from breast MRI scans with standard pathology and clinical factors. She said the approach could give clinicians insight into recurrence risk using information already captured in a patient’s MRI.
Stevens also said the tool has the potential to expand access to information that could help doctors and patients make decisions with greater clarity and confidence. The article characterizes TumorSight Risk as the world’s first MRI-derived tool for predicting breast cancer recurrence.
AuntMinnie’s headline separately reports FDA clearance for SimBioSys breast cancer risk software, while headlines from Fierce Biotech, Unite.AI and PR Newswire also describe FDA clearance for a breast cancer recurrence tool. Fierce Biotech’s headline calls the tool MRI-derived and Nvidia-powered; PR Newswire’s headline calls it AI-powered and MRI-derived.
Those headlines do not provide further details about the software’s operation or the clearance. The article places the software in the context of breast cancer, which it says accounts for about one in three new cancers in women each year.
It does not provide additional information about how clinicians should interpret an individual score, or describe how the clearance may affect treatment decisions. Stevens’s comments present the software as a source of information for doctors and patients, rather than as a treatment or a replacement for clinical judgment.
For now, the stated functions are risk estimation and categorization: the software uses MRI scans and clinical factors, calculates five- and 10-year estimates, and assigns a score and risk band. The account does not specify how often clinicians will use the tool or what decisions may follow from a particular score.
SimBioSys’s announcement and the FDA clearance establish the event; the potential value for clinical decision-making is Stevens’s stated view.
Why it matters
- For women with breast cancer, the software is intended to estimate recurrence risk over five- and 10-year periods using MRI scans and clinical factors.
- The score ranges from 0 to 100 and is categorized as high, intermediate or low risk, giving clinicians and patients a defined risk-assessment format.
- SimBioSys President and CEO Stacey Stevens said the tool could help doctors and patients make decisions with greater clarity and confidence.
What to watch next
- Whether SimBioSys provides further information about how clinicians should interpret TumorSight Risk’s scores and risk categories.
- Whether SimBioSys describes how the five- and 10-year estimates may inform decisions by doctors and patients.
- Whether the FDA or SimBioSys provides further details about the software’s cleared use.
How it's being covered
Coverage analysisShow details5 source articles · 5 unique outlets · 4 distinct reportsCoverage mix: Center Only· 3 CenterWhere the outlets are based: US/Canada 60% · Unknown 40%
- Coverage is currently concentrated among Center-rated outlets (3 of 3 rated sources); comparatively few Left or Right-rated outlets have published on the event.
How outlets' accounts compare
Timeline
Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.- Genomic Health introduced the Oncotype DX breast recurrence assay in 2004; it uses gene-expression measurements from tumor tissue to inform treatment decisions for certain patients with early-stage disease.Background · from our historical context
How we got here
Before TumorSight Risk, clinicians already had tools for estimating breast-cancer recurrence. Genomic Health introduced the Oncotype DX breast recurrence assay in 2004; it uses gene-expression measurements from tumor tissue to inform treatment decisions for certain patients with early-stage disease.
The Medical Device Amendments of 1976 gave the Food and Drug Administration authority to regulate medical devices, including software that performs a medical function. The FDA’s 1997 De Novo pathway later created a route for certain novel, low- to moderate-risk devices without a suitable existing classification.
Original sources
5 articles from 5 outletsEvery story links to the reporting it was built from. How we choose sources
Spotted a factual error, a broken link or a misleading summary? Tell us.